Explore
Anticancer Drugs
Niamh M O’Boyle and Mary J Meegan
2019
0 Ungluers have
Faved this Work
Login to Fave
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 155 times via unglue.it ebook links.
- 113 - pdf (CC BY-NC-ND) at Unglue.it.
Keywords
- 3-vinylazetidin-2-ones
- 5-fluorouracil
- ?-lactam
- abiraterone
- and cancer therapy
- androgens
- anti-cancer drugs
- antibody
- anticancer
- antimitotic
- antiproliferative activity
- biomarker profiling
- Cancer
- cancer drug design
- cancer immunotherapy
- chemical linker
- cisplatin
- cisplatin resistance
- Combretastatin A-4
- conjugate and hybrid drugs
- conjugate and hybrid drugs, cisplatin resistance, topoisomerase inhibitors
- COX-1 inhibitor
- cyclooxygenase-1
- cyclooxygenase-2
- CYP17A1
- Cytochrome P450
- dehydroepiandrosterone
- drug conjugation
- Drug delivery
- DSD
- ellipticine
- Glioblastoma
- graphene oxide
- Heterocyclic chemistry
- heteropolysaccharide
- indole
- Inflammation
- intestinal mucositis
- maghemite
- magnetic targeting
- Metabolism
- microtubule targeted drugs
- NCI screen
- oesophageal cancer
- P450c17
- prostate cancer
- radiation
- snticancer drugs
- steroidogenesis
- topoisomerase II
- topoisomerase inhibitors
- treatment resistance
- tubulin
- tumorigenesis
- [18F]FDG PET/CT
Links
DOI: 10.3390/books978-3-03921-587-4Editions
